Chapter 43. Lymphoblastic Lymphoma

  1. Mark A. Crowther MD, MSc, FRCPC Professor Division Director2,3,
  2. Jeff Ginsberg MD, FRCPC Professor4,
  3. Holger J. Schünemann MD, PhD, MSc, FACP, FCCP Professor5,6,
  4. Ralph M. Meyer MD, FRCPC Director Professor7,8 and
  5. Richard Lottenberg MD, FACP Professor9
  1. Tyler Y. Kang MD Hematology/Oncology Fellow and
  2. John W. Sweetenham MD, FRCP

Published Online: 4 FEB 2009

DOI: 10.1002/9781444300857.ch43

Evidence-Based Hematology

Evidence-Based Hematology

How to Cite

Kang, T. Y. and Sweetenham, J. W. (2008) Lymphoblastic Lymphoma, in Evidence-Based Hematology (eds M. A. Crowther, J. Ginsberg, H. J. Schünemann, R. M. Meyer and R. Lottenberg), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444300857.ch43

Editor Information

  1. 2

    Division of Hematology, McMaster University, Hamilton, Ontario, Canada

  2. 3

    St. Joseph's Hospital, Hamilton, Ontario, Canada

  3. 4

    Department of Medicine, McMaster University, Hamilton, Canada

  4. 5

    CLARITY Research Group, Department of Epidemiology, Italian National Cancer Institute Regina Elena, Rome, Italy

  5. 6

    McMaster University, Hamilton, Canada

  6. 7

    National Cancer Institute of Canada, Clinical Trials Group, Edith Eisenhauer Chair in Clinical Cancer Research, Queen's University, Kingston, Ontario, Canada

  7. 8

    Departments of Oncology and Medicine, Queen's University, Kingston, Ontario, Canada

  8. 9

    Division of Hematology/Oncology, Department of Medicine, University of Florida College of Medicine, Gainesville, Florida, USA

Author Information

  1. Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio, USA

Publication History

  1. Published Online: 4 FEB 2009
  2. Published Print: 27 JUN 2008

ISBN Information

Print ISBN: 9781405157476

Online ISBN: 9781444300857



  • Lymphoblastic lymphoma (LBL);
  • aggressive ALL-type regimens and outcome improvement;
  • comparison of treatment regimens and outcome;
  • CNS prophylaxis and improved outcome;
  • stem cell transplantation after first remission and improved outcome;
  • mediastinal radiation in improved outcome;
  • therapy with autologous transplantation preferred


This chapter contains sections titled:

  • Introduction

  • Questions

  • Literature-search strategy and inclusion

  • Do aggressive ALL-type regimens improve outcome?

  • Does CNS prophylaxis improve outcome, including survival?

  • Does stem cell transplantation after first remission improve outcome?

  • Does the type of transplantation (autologous vs. allogeneic) influence outcome?

  • Does mediastinal radiation improve outcome?

  • References